Kyverna Therapeutics, Inc. (KYTX)

NASDAQ: KYTX · Real-Time Price · USD

6.63

-0.43 (-6.09%)

At close: Oct 10, 2025, 4:00 PM EDT

6.31

-0.32 (-4.83%)

After-hours: Oct 10, 2025, 7:13 PM EDT

Kyverna Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022
Period Ending	Oct '25 Oct 10, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Cap	287	162	-	-
Market Cap Growth	18.88%	-	-	-
Enterprise Value	95.23	-120.05	129.19	77.64
Last Close Price	6.63	3.74	-	-
PE Ratio	-	-1.12	0	0
PB Ratio	1.66	0.61	0	0
P/TBV Ratio	1.55	0.54	-	-
P/FCF Ratio	-	-1.39	0	0
P/OCF Ratio	-	-1.41	0	0
EV/Sales Ratio	-	-	-	11.05
EV/EBITDA Ratio	-	0.85	-2.13	-2.74
EV/EBIT Ratio	-	0.84	-2.07	-2.64
EV/FCF Ratio	-	1.03	-2.44	-2.11
Debt / Equity Ratio	0.01	0.02	0.13	0.18
Debt / EBITDA Ratio	-0.04	-0.06	-0.15	-0.37
Debt / FCF Ratio	-0.04	-0.07	-0.17	-0.29
Asset Turnover	0	0	0	0.10
Quick Ratio	5.32	8.47	2.90	4.29
Current Ratio	5.39	8.61	3.05	4.45
Return on Equity (ROE)	-70.30%	-80.63%	-125.72%	-61.86%
Return on Assets (ROA)	-64.63%	-75.09%	-87.82%	-43.91%
Return on Capital (ROIC)	-1017.33%	-804.88%	-373.68%	-184.23%
Return on Capital Employed (ROCE)	-75.01%	-87.43%	-113.15%	-53.45%
Earnings Yield	-52.73%	-89.04%	-	-
FCF Yield	-47.19%	-72.05%	-	-
Buyback Yield / Dilution	0.00%	-211.25%	-	-
Total Shareholder Return	-	-211.25%	-	-

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q